Praluent is Fine

You said "And try harder to spell". Do you use proper grammar much?

 

"Reallocate the sales force" LOL!!
That's NOT how Regeneron works - there'll be no reallocation.
Sanofi covers half our salaries & we're contracted with them for sarilumab & dupilumab.
Those teams are staffed.
When Praluent's done, so are we.
Regeneron will wipe the slate clean and start fresh with Teva on the next product.

 

So why will a physician prescribe a $30K treatment when a $10 ointment exists ? Maybe they'll use an existing channel and get Humira for free post insurance? This is the current scenario for many patients.

What about generic Humira/Enbrel?

Again, why will anyone (Payers included) want to take on another drug for $30K/year?

Too little too late. Even if FDA approves this garbage, it's DEAD!!!

 

Lower market forecasts published for Dupi.

 

The product will bomb. It's a good product but too expensive and the PBM's will slaughter it. It's been nice to sit around since November and go shopping and go to the gym and amp up my kids car pooling. I'm hoping the delay runs to June as I can sell some more real estate on the side . I love Regeneron. I just hope sanofi does most of the work as I have responsibilities for car pooling and my yoga classes.

 

Premature drug degradation severely reduces the potency of dupi in 6 months. Product disaster. Lawsuit in the making.

 

First off, if you're going to attempt to make an intelligent post, at least get the terminology correct. There are no "generics" in the biologic space. They're biosimilars, and the first SC biosimilar won't hit the derm space until probably 2021 as Humira's exclusivity patent expires.

Secondly, the only thing Enbrel/Humira have in common with Dupilumab is that they're self-injected SC biologics that derms can prescribe...aside from that, they're used in completely different disease states.

That being said, If the market can sustain a $20k/yr small molecule pill in a disease category with 7 other competitors that are all north of $30k, it can sustain a $30k product in a disease category with no alternative.

 

You're confusing the products. Psoriasis is what you're referring to and Dupi is for Atopic Dermatitis. Fucking r*****!

 

Go back and try again with your reading comprehension.

It was stated that Enbrel/Humira are in different disease categories than dupilumab.

It also referenced the pricing for Otezla and Xeljanz, two small molecule products with biologic price tags.

There is no alternative for dupilumab, (which was also stated).

Sorry you were passed over for the job. I'm sure you did fantastic in the panel interview.

 

Listen, Mr. Confused,

Again, Humira/Enbrea are for Psoriasis (AI area) and Dupi is for Atopic Derm/Asthma. Complete different Indications/diseases, not DISEASE STATES. I like how you're so hubris ridden there's no way through that thick skull.

There are topicals, UV treatments, combinations thereof for mid/severe atopic dermatitis. Kids grow out of asthma and dermatitis. Look it up fool!

My original point indicated low uptake in the Payer/physician world due to Dupi's price. You mentioned some small molecule drugs .....way off topic. Maybe you need to drink a few more gins and .....

......Go back to sleep you fucking moron.

 

Well I at least got you to suck on my dick before I left

 

Mr. Confused,

Enbrel/ Humira is for AIR, i.e, psoriasis. Dupi is for Atopic derm/ asthma which kids grow out of. Complete different diseases, not just disease states. Even if you changed the wording, you're still wrong.

Alternatives to Dupi are tropicals, UV treatments and combinations, way cheaper than Dupi. Why will any physician/ payer use Dupi? No market Uptake.

We hired the wrong guy. Got enough morons around during here.

 

I sold in that market for 10+ years. I'd say I have a decent knowledge of that "disease state."

You seem to not realize there are more approved alternatives to plaque psoriasis than AD. Everything you mentioned (even "tropicals") is also an alternative for PSO....and systemic DMARDs in that space are actually approved by the FDA.

Yes the vast majority of kids grow out of it...the market is obviously not near the same size as the PSO market, but there will be uptake.

The best thing for this company is if you're not in any type of strategic position. The worst morons are those that are misguided in their level of intelligence.

 

Whatever, we will all soon find out how the market reacts. Now go sell something.

 

Dupi is doomed. You all were duped if you took this job. Anything that's tied to Sanofi will be dead in the water. Just look at their drug launch successes. I'd get my resume updated. You'll see all too soon.

 

Launching from a zombie facility (way to come back from near death)!
Limited physician uptake - mind as well go from ointments to suppositories.
Limited (meaning none) successful launches at Sanofi/Regeneron.
Limited patent rights on IL-4 pathways.
Limited dermatology experience in both companies for the market.
Limited patients and real world efficacy data.
Normally this means limited success but we're full of people who jump on the shit wagon at REGN!

Dupi will be successful, for sure!

 

douche dupe now

 

Real clever response there r*****

 

I just spoke with one of my clinicians yesterday. She said she has, perhaps, 3 patients who can benefit from dupe. She said it's mainly in children.

It's going to be a very limited market until the ped indication is here. Hopefully the goals will be super low.